Coronavirus illness 2019 (COVID-19) is an infectious illness precipitated by the newly found coronavirus, SARS-CoV-2. Increased severity of COVID-19 has been noticed in sufferers with diabetes mellitus (DM). This research aimed to determine common transcriptional signatures, regulators and pathways between COVID-19 and DM. We have built-in human whole-genome transcriptomic datasets from COVID-19 and DM, adopted by practical evaluation with gene ontology (GO) and pathway analyses.
In peripheral blood mononuclear cells (PBMCs), among the many upregulated differentially expressed genes (DEGs), 32 had been discovered to be generally modulated in COVID-19 and sort 2 diabetes (T2D), whereas 10 DEGs had been generally downregulated. As regards sort 1 diabetes (T1D), 21 DEGs had been generally upregulated, and 29 DEGs had been generally downregulated in COVID-19 and T1D. Moreover, 35 DEGs had been generally upregulated in SARS-CoV-2 contaminated pancreas organoids and T2D islets, whereas 14 had been generally downregulated.
Several GO phrases had been present in common between COVID-19 and DM. Prediction of the putative transcription components concerned within the upregulation of genes in COVID-19 and DM recognized RELA to be implicated in each PBMCs and pancreas. Here, for the primary time, we have now characterised the organic processes and pathways generally dysregulated in COVID-19 and DM, which might be within the subsequent future used for the design of customized remedy of COVID-19 sufferers affected by DM as comorbidity.
Cisplatin’s potential for sort 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1
Cisplatin is a DNA-damaging chemotherapeutic agent used for treating most cancers. Based on cDNA dataset analysis, we investigated how cisplatin modified gene expression and noticed cisplatin-induced dysregulation and system-level variations referring to insulin resistance and sort 2 diabetes mellitus (T2DM). T2DM is a multifactorial illness affecting 462 million individuals on the planet, and drug-induced T2DM is a severe problem.
To perceive this etiology, we designed an integrative, system-level research to determine associations between cisplatin-induced differentially expressed genes (DEGs) and T2DM. From an inventory of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis issue (FAS), and sestrin-1 (SESN1) genes chargeable for modifying signaling pathways, together with the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. These enriched pathways had been expressively related to the illness.
We noticed important gene signatures, together with SMAD3, IRS, PDK1, PRKAA1, AKT, SOS, RAS, GRB2, MEK1/2, and ERK, interacting with supply genes. This research revealed the worth of system genetics for figuring out the cisplatin-induced genetic variants chargeable for the development of T2DM. Also, by cross-validating gene expression information for T2DM islets, we discovered that downregulating IRS and PRK households is important in insulin and T2DM signaling pathways.
Cisplatin, by inhibiting CDKN1A, FAS, and SESN1, promotes IRS and PRK exercise in the same technique to rosiglitazone (a preferred drug used for T2DM remedy). Our integrative, network-based strategy might help in understanding the drug-induced pathophysiological mechanisms of diabetes.
Relationship between cardiovascular and kidney disease in a sample of patients with diabetes in today’s world
Kidney disease is one of the microvascular complications of diabetes mellitus (DM) with little research and a great relationship with cardiovascular disease (CVD). The objective of this work is to characterize the prevalence of kidney disease in a population of patients with type 2 diabetes who attend outpatient management by cardiology, determine its degree of investigation and its possible effect on the achievement of therapeutic objectives and the use of antidiabetics with cardiorenal protective effect.
Methods: Cross-sectional, observational and multicenter study carried out in 44 centers in Argentina between May and July 2019. Results: 693 patients were included with an established CVD prevalence of 47.5% (329 patients) and 42.3% of microvascular disease . Albuminuria was only assessed in 46.2% of the patients and it was significantly higher in the group with IR. CVD in patients with IR was higher than in those without IR (64.8% vs. 42.2%; p = 0.0001). The presence of albuminuria was accompanied by a higher prevalence of CVD.
The scope of the therapeutic targets was limited and no differences were recognized as a function of RI, with the exception of the LDL target. Low prescription of antidiabetic drugs with proven cardiorenal benefit was observed. Conclusions: The work highlights the importance of the active search for kidney disease in patients with diabetes, which reveals the low scope of therapeutic goals and the prescription of antidiabetic drugs with cardiorenal benefit.
Evaluation of affiliation research and a scientific evaluation and meta-analysis of VDR polymorphisms in sort 2 diabetes mellitus threat
Numerous unique research and four revealed meta-analyses have reported the affiliation between the Vitamin D receptor (VDR) BsmI, FokI, ApaI, and TaqI polymorphisms and sort 2 diabetes mellitus (T2DM) threat. However, the outcomes had been inconsistent.
Therefore, an up to date meta-analysis was carried out to additional discover these points.To additional discover the affiliation between the VDR BsmI, FokI, ApaI, and TaqI polymorphisms and T2DM threat.PubMed, EMBASE, Scopus, and Wanfang databases had been searched. The following search technique had been used: (VDR OR vitamin D receptor) AND (polymorphism OR variant OR mutation) AND (diabetes OR mellitus OR diabetes mellitus).
Pooled crude odds ratios with 95% confidence intervals had been utilized to guage the energy of affiliation in 5 genetic fashions. Statistical heterogeneity, the take a look at of publication bias, and sensitivity analysis had been carried out utilizing the STATA software program (Version 12.0). To consider the credibility of statistically important associations, we utilized the false-positive report chances (FPRP) and Bayesian false discovery chance (BFDP) take a look at.
Overall, the VDR BsmI polymorphism was related to a considerably decreased T2DM threat in Asians; the VDR FokI polymorphism was related to a considerably decreased T2DM threat in Asians, African international locations, and Asian international locations; the VDR ApaI polymorphism was related to a considerably decreased T2DM threat in Caucasians and North American international locations.On the VDR ApaI polymorphism, a considerably elevated T2DM threat was present in a blended inhabitants.
cDNA - Human Tumor Cell Line: Hela |
|||
| C1255811 | Biochain | 40 reactions | 385 EUR |
Purified Exosomes: HeLa Human Cell Line |
|||
| EXOP-405A-1 | SBI | 50 µg | 409 EUR |
Total RNA - Human Tumor Cell Line: Hela |
|||
| R1255811-50 | Biochain | 50 ug | 191 EUR |
H2O2 stimulated HeLa Cell Lysate (Human epithelial cell line) |
|||
| LF-R0002 | Abfrontier | Each 100 ul | 145.2 EUR |
|
Description: HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate - H2O2 stimulated |
|||
Genomic DNA - Human Tumor Cell Line: Hela |
|||
| D1255811 | Biochain | 100 ug | 245 EUR |
Total Protein - Human Tumor Cell Line: Hela |
|||
| P1255811 | Biochain | 1 mg | 188 EUR |
Membrane Protein - Human Tumor Cell Line: Hela |
|||
| P3255811 | Biochain | 0.1 mg | 270 EUR |
ACE2 - HeLa Recombinant Cell Line |
|||
| 79958 | BPS Bioscience | 2 vials | 4950 EUR |
|
Description: Recombinant clonal stable HeLa cell line constitutively expressing full length human ACE2, Genbank #NM_021804.3). Surface expression of ACE2 was confirmed by flow cytometry. |
|||
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU168183 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
|||
| TU072380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU269725 | ABM | 1.0 ml | Ask for price |
Hela / Cas9 (Bad) Stable Cell Line |
|||
| SC045-Cas9-Bsd | GenTarget | 2 x 106 cell/ml x 1ml | 1269.6 EUR |
|
Description: Cas9 expression stable cell line with Blasticidin resistance in Hela human cervical cancer cells. |
|||
Gene Knock-Out HR Targeting Vector [MCS1-EF1α-RFP-T2A-Puro-pA-MCS2] |
|||
| HR110PA-1 | SBI | 10 ug | 933 EUR |
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2] |
|||
| HR410PA-1 | SBI | 10 ug | 933 EUR |
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2] |
|||
| HR510PA-1 | SBI | 10 ug | 933 EUR |
B2M Knockout Jurkat Cell Line |
|||
| 78342 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from Jurkat cells. |
|||
TCR Knockout Jurkat Cell Line |
|||
| 78539 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: The TCR Knockout Jurkat cell line was generated by CRISPR/Cas9 genome editing to remove the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα and β chains. |
|||
293AD Cell Line |
|||
| AD-100 | Cell Biolabs | 1 vial | 553.2 EUR |
|
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area. |
|||
B2M Knockout THP-1 Cell Line |
|||
| 78389 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from THP-1 cells. |
|||
Inducible GFP Hela stable cell line |
|||
| SC036 | GenTarget | 2 x 106 cell/ml x 1ml | 1800 EUR |
|
Description: InducibleGFP expression stable cell line in Hela cells, with Neomycin and puromycin resitance |
|||
Inducible RFP Hela stable cell line |
|||
| SC037 | GenTarget | 2 x 106 cell/ml x 1ml | 1800 EUR |
|
Description: Inducible RFP expression stable cell line in Hela with Blasticidin and Puromycin resistance |
|||
293AAV Cell Line |
|||
| AAV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area. |
|||
293LTV Cell Line |
|||
| LTV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area. |
|||
293RTV Cell Line |
|||
| RV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area. |
|||
Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out |
|||
| HR100PA-1 | SBI | 10 ug | 868 EUR |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU118183 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
| TU022380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU219725 | ABM | 1.0 ml | Ask for price |
CIITA Knockout THP-1 Cell Line |
|||
| 78390 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: CIITA (Class II Transactivator) has been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing. |
|||
TCR/B2M Knockout Jurkat Cell Line |
|||
| 78552 | BPS Bioscience | 2 vials | 8645 EUR |
|
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from Jurkat cells to generate the TCR Knockout Jurkat cell Line (BPS Bioscience #78539). These TCR knockout cells were then used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. |
|||
293/GFP Cell Line |
|||
| AKR-200 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
T47D/GFP Cell Line |
|||
| AKR-208 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
A549/GFP Cell Line |
|||
| AKR-209 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
293/Cas9 Cell Line |
|||
| AKR-5110 | Cell Biolabs | 1 vial | 686.4 EUR |
NIH3T3/GFP Cell Line |
|||
| AKR-214 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
NIH3T3/Cas9 Cell Line |
|||
| AKR-5104 | Cell Biolabs | 1 vial | 686.4 EUR |
TARGATT? Knock-in iPSC Quick Knockin Kit |
|||
| AST-1101 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
FCGR2A (CD32A) Knockout Jurkat Cell Line |
|||
| 78549 | BPS Bioscience | 2 vials | 6500 EUR |
|
Description: The FCGR2A Knockout Jurkat cell line was generated by CRISPR/Cas9 genome editing to remove FCGR2A (CD32A), the gene encoding protein FcγRIIa (Fragment crystallizable gamma receptor II a, also known as FcGRIIa, Fc-gamma-RIIa, and CD32A). |
|||
MCF-7/Luc Cell Line |
|||
| AKR-234 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
SKOV-3/Luc Cell Line |
|||
| AKR-232 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
HeLa Cell Slide |
|||
| 17-001 | ProSci | 1 pack | 216.6 EUR |
|
Description: HeLa S3 (cervix; adenocarcinoma) |
|||
OVCAR-5/RFP Cell Line |
|||
| AKR-254 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
HeLa Cell Extract |
|||
| 30R-AG012 | Fitzgerald | 100 ug | 418.8 EUR |
|
Description: Glutathiolated human epithelial carcinoma cell (HeLa) extract |
|||
B2M/CIITA Double Knockout THP-1 Cell Line |
|||
| 78391 | BPS Bioscience | 2 vials | 9500 EUR |
|
Description: Both B2M (Beta-2-Microglobulin) and CIITA (Class II Transactivator) have been genetically removed from THP-1 cells using CRISPR/Cas9 genome editing. |
|||
Human Hela Whole Cell Lysate |
|||
| LYSATE0023 | BosterBio | 200ug | 180 EUR |
|
Description: This cell lysate is prepared from human hela using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C. |
|||
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway) |
|||
| 79041 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene. |
|||
HeLa Cell Lysate (Whole Cell) |
|||
| LYSATE0001 | Cusabio | 200ug | 180 EUR |
|
Description: This whole cell lysate is prepared from Hela cells using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C. |
|||
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
| K2069901 | ABM | 3 x 1.0 ug | 406.8 EUR |
TARGATT? Knock-in iPSC Genotyping Kit |
|||
| AST-1102 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
|||
| RV-101 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
|||
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
|||
| RV-103 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector. |
|||
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
|||
| RV-102 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
|||
Total Protein - Murine Embryonic Stem Cell Line D3 |
|||
| CBA-305 | Cell Biolabs | 500 ?g | 414 EUR |
|
Description:
|
|||
B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
| 78363 | BPS Bioscience | 2 vials | 11095 EUR |
|
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells. Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line |
|||
| 78556 | BPS Bioscience | 2 vials | 12205 EUR |
|
Description: This cell line is a knockout of TCR (T Cell Receptor). The TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.This cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621). |
|||
TCR/B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
| 78557 | BPS Bioscience | 2 vials | 16695 EUR |
|
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells to generate the TCR Knockout NFAT Luciferase Reporter Jurkat cell Line (BPS Bioscience #78556). These TCR knockout cells were used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. _x000D_Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
HeLa cells |
|||
| C0008001 | Addexbio | One Frozen vial | 546 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K2069902 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K2069903 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K2069904 | ABM | 1.0 ug DNA | 184.8 EUR |
Cas9-Expressing HeLa Cell Pool |
|||
| 78161 | BPS Bioscience | 2 vials | 795 EUR |
|
Description: Cas9 (Streptococcus pyogenes CRISPR associated protein 9) is an endonuclease enzyme that, when recruited to a specific DNA sequence by the sgRNA (single guide RNA), introduces a double stranded break into the DNA. This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the targeted gene. Cas9-expressing HeLa cells can be transduced or electroporated with sgRNA targeting a gene of interest to quickly generate knock-out cell pools or cell lines. |
|||
Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration |
|||
| HR720PA-1 | SBI | 10 µg | 1071 EUR |
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration |
|||
| HR700PA-1 | SBI | 10 µg | 1071 EUR |
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration |
|||
| HR710PA-1 | SBI | 10 µg | 1071 EUR |
Human HeLa Whole Cell Lysate, TNFa Stimulated |
|||
| HCL-2000 | Alpha Diagnostics | 100ug | 255.6 EUR |
Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1α-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2] |
|||
| HR210PA-1 | SBI | 10 ug | 1071 EUR |
Human Cell Line Array I (293, A-431, A549, Hela S3, Hep G2 and MCF7) (5 slides/pk) |
|||
| HCLA-17601 | Alpha Diagnostics | 1 pk | 300 EUR |
Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate |
|||
| HCL-2009 | Alpha Diagnostics | 1 mg | 628.8 EUR |
Human ; HeLa (#1) |
|||
| 02-723 | Sceti | 100ng | 481.2 EUR |
|
Description: The Human ; HeLa (#1) is available in Europe and for worldwide shipping via Gentaur. |
|||
Rrad/ Rat Rrad ELISA Kit |
|||
| ELI-14921r | Lifescience Market | 96 Tests | 1063.2 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract |
|||
| HCL-2008 | Alpha Diagnostics | 100ug | 270 EUR |
RRAD ELISA KIT|Human |
|||
| EF005507 | Lifescience Market | 96 Tests | 826.8 EUR |
Rrad sgRNA CRISPR Lentivector set (Rat) |
|||
| K7052701 | ABM | 3 x 1.0 ug | 406.8 EUR |
Human RRAD shRNA Plasmid |
|||
| 20-abx954199 | Abbexa |
|
|
Rrad sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3480701 | ABM | 3 x 1.0 ug | 406.8 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2069905 | ABM | 3 x 1.0 ug | 451.2 EUR |
RRAD Recombinant Protein (Human) |
|||
| RP095493 | ABM | 100 ug | Ask for price |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K2069906 | ABM | 1.0 ug DNA | 200.4 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K2069907 | ABM | 1.0 ug DNA | 200.4 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K2069908 | ABM | 1.0 ug DNA | 200.4 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7052702 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7052703 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7052704 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD ORF Vector (Human) (pORF) |
|||
| ORF031832 | ABM | 1.0 ug DNA | 486 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3480702 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3480703 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3480704 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD siRNA |
|||
| 20-abx932133 | Abbexa |
|
|
RRAD Peptide |
|||
| 43-008P | ProSci | 0.1 mg | 405.6 EUR |
|
Description: RRAD Peptide |
|||
RRAD Antibody |
|||
| 37229-100ul | SAB | 100ul | 302.4 EUR |
RRAD antibody |
|||
| 70R-5797 | Fitzgerald | 50 ug | 560.4 EUR |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
|||
RRAD antibody |
|||
| 70R-5798 | Fitzgerald | 50 ug | 560.4 EUR |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
|||
RRAD antibody |
|||
| 70R-50359 | Fitzgerald | 100 ul | 292.8 EUR |
|
Description: Purified Polyclonal RRAD antibody |
|||
RRAD Antibody |
|||
| 1-CSB-PA003910 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
|||
RRAD Antibody |
|||
| CSB-PA233809- | Cusabio | each | 402 EUR |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
|||
RRAD Antibody |
|||
| CSB-PA233809-100ul | Cusabio | 100ul | 379.2 EUR |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
|||
RRAD Antibody |
|||
| 1-CSB-PA248209 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
|||
RRAD Antibody |
|||
| 1-CSB-PA779820 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
|||
RRAD Antibody |
|||
| R34275-100UG | NSJ Bioreagents | 100 ug | 339.15 EUR |
|
Description: Additional name(s) for this target protein: Ras-related associated with diabetes |
|||
HeLa Cell Slide (Human (31 yrs, Female) cervix epithelioid carcinoma) (5 slides/pk) |
|||
| HCLS-17001 | Alpha Diagnostics | 1 pk | 300 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - TNFa Stimulated |
|||
| HCL-2007 | Alpha Diagnostics | 100ug | 270 EUR |
Hela-RFP stable cells |
|||
| SC031-Puro | GenTarget | 2 x 106 cell/ml x 1ml | 930 EUR |
|
Description: RFP expression stable cell line in Hela cells with Puromycin marker. |
|||
hspCas9 AAVS1 Safe Harbor Knock-in Donor (AAVS1-SA-puro-EF1-hspCas9) |
|||
| CAS620A-1 | SBI | 10 ug | 1106 EUR |
Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Etoposide Stimulated |
|||
| HCL-2011 | Alpha Diagnostics | 100ug | 255.6 EUR |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
| CBA-135 | Cell Biolabs | 96 assays | 985.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
| CBA-135-5 | Cell Biolabs | 5 x 96 assays | 4027.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
| CBA-140 | Cell Biolabs | 96 assays | 1027.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
| CBA-140-5 | Cell Biolabs | 5 x 96 assays | 4179.6 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|||
| CBA-325 | Cell Biolabs | 96 assays | 1027.2 EUR |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
|||
StemTAG Stem Cell Colony Formation Assay (Cell Recovery Compatible) |
|||
| CBA-325-5 | Cell Biolabs | 5 x 96 assays | 4033.2 EUR |
|
Description: Our StemTAG 96-Well Stem Cell Colony Formation Assay provides a high-throughput method to quantify ES cells in just 7-10 days, and no manual cell counting is required. Once colonies are formed, they may be analyzed in three different ways: 1. Lyse cells, then quantify in a fluorescence plate reader using dye included in the kit; 2. Lyse cells, then quantify alkaline phosphatase activity using reagents provided; or 3. Recover colonies from matrix for further culture or analysis. |
|||
HeLa Whole Cell Lysate (Epitheloid carinoma cells) |
|||
| HELA-100 | Alpha Diagnostics | 100 ug | 196.8 EUR |
HeLa Whole Cell Lysate (Epitheloid carinoma cells) |
|||
| HELA-50 | Alpha Diagnostics | 50 ug | 153.6 EUR |
Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Doxorubicin Stimulated |
|||
| HCL-2010 | Alpha Diagnostics | 100ug | 255.6 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Etoposide Stimulated |
|||
| HCL-2005 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Nocodozole Stimulated |
|||
| HCL-2006 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Doxorubicin Stimulated |
|||
| HCL-2004 | Alpha Diagnostics | 100ug | 270 EUR |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size |
|||
| CBA-135-T | Cell Biolabs | 24 assays | 518.4 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size |
|||
| CBA-140-T | Cell Biolabs | 24 assays | 547.2 EUR |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
Cas9 (CRISPR Associated Protein 9) ELISA Kit |
|||
| PRB-5079 | Cell Biolabs | 96 assays | 686.4 EUR |
Collagen-based Cell Contraction Assay |
|||
| CBA-201 | Cell Biolabs | 24 assays | 582 EUR |
|
Description: Cell Biolabs? Collagen-based Contraction Assay Kit provides a simple system to assess cell contractivity in vitro and screen cell contraction mediators. Each kit provides sufficient quantities to perform up to 24 assays in a 24-well plate. The kit can be also used in culturing cells in 3D collagen matrix. |
|||
CytoSelect MTT Cell Proliferation Assay |
|||
| CBA-252 | Cell Biolabs | 960 assays | 490.8 EUR |
|
Description: Cell Biolabs? CytoSelect MTT Cell Proliferation Assay provides a colorimetric format for measuring and monitoring cell proliferation. The kit contains sufficient reagents for the evaluation of 960 assays in 96-well plates or 192 assays in 24-well plates. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then detected with the proliferation reagent, which is converted in live cells from the yellow tetrazole MTT to the purple formazan form by a cellular reductase (Figure 1). An increase in cell proliferation is accompanied by an increased signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. |
|||
Radius 24-Well Cell Migration Assay |
|||
| CBA-125 | Cell Biolabs | 24 assays | 602.4 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 24-Well Cell Migration Assay |
|||
| CBA-125-5 | Cell Biolabs | 5 x 24 assays | 2362.8 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 96-Well Cell Migration Assay |
|||
| CBA-126 | Cell Biolabs | 96 assays | 686.4 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 96-Well Cell Migration Assay |
|||
| CBA-126-5 | Cell Biolabs | 5 x 96 assays | 2697.6 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 384-Well Cell Migration Assay |
|||
| CBA-127 | Cell Biolabs | 384 assays | 721.2 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 384-Well Cell Migration Assay |
|||
| CBA-127-5 | Cell Biolabs | 5 x 384 wells | 2802 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 48-Well Cell Migration Assay |
|||
| CBA-5037 | Cell Biolabs | 48 assays | 622.8 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
Radius 48-Well Cell Migration Assay |
|||
| CBA-5037-5 | Cell Biolabs | 5 x 48 assays | 2454 EUR |
|
Description: The Radius Cell Migration Assay provides a unique alternative to conventional cell migration assays using the Boyden chamber. Unlike Boyden chamber assays which may only be analyzed at endpoint, the Radius assay uses a proprietary cell culture plate containing a carefully-defined biocompatible hydrogel (Radius gel) spot centralized at the bottom of each well. When cells are seeded in the well, they will attach everywhere except on the Radius gel, creating a cell-free zone. Following cell seeding the Radius gel is removed, allowing migratory cells to move across the area and close the gap. |
|||
HIF-1 Alpha Cell Based ELISA Kit |
|||
| CBA-281 | Cell Biolabs | 96 assays | 734.4 EUR |
|
Description: Cell Biolabs? HIF-1 Cell Based ELISA Kit is an immunoassay developed for rapid detection of HIF-1 Alpha in fixed cells. Cells on a microplate are stimulated for HIF-1 Alpha stabilization, fixed, permeabilized, and then neutralized in the well. HIF-1 Alpha is then detected with an anti-HIF-1 alpha antibody followed by an HRP conjugated secondary antibody. Each kit provides sufficient reagents to perform up to a total of 96 assays and can detect HIF-1 Alpha from human, mouse, or rat. |
|||
Hela-TetR (Puro) stable cells |
|||
| SC035-Puro | GenTarget | 2 x 106 cell/ml x 1ml | 1452 EUR |
|
Description: tetracycline repressor expression Hela stable cell line with Puromycin marker |
|||
Cas13a (CRISPR Associated Protein 13a, C2c2) ELISA Kit |
|||
| PRB-5091 | Cell Biolabs | 96 assays | 686.4 EUR |
CytoSelect BrdU Cell Proliferation ELISA Kit |
|||
| CBA-251 | Cell Biolabs | 96 assays | 637.2 EUR |
|
Description: The CytoSelect BrdU Cell Proliferation ELISA Kit detects BrdU incorporated into cellular DNA during cell proliferation using an anti-BrdU antibody. When cells are incubated in media containing BrdU, the pyrimidine analog is incorporated in place of thymidine into the newly synthesized DNA of proliferating cells. Once the labeling media is removed, the cells are fixed and the DNA is denatured in one step with a fix/denature solution (denaturation of the DNA is necessary to improve the accessibility of the incorporated BrdU for detection). Then an anti-BrdU mouse monoclonal antibody is added followed by an HRP conjugated secondary antibody to detect the incorporated BrdU. The magnitude of the absorbance for the developed color is proportional to the quantity of BrdU incorporated into cells and can be directly correlated to cell proliferation. |
|||
CytoSelect 96-well Cell Transformation Assay |
|||
| CBA-130 | Cell Biolabs | 96 assays | 866.4 EUR |
|
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader. |
|||
CytoSelect 96-well Cell Transformation Assay |
|||
| CBA-130-5 | Cell Biolabs | 5 x 96 assays | 3463.2 EUR |
|
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader. |
|||
CytoSelect 24-well Cell Invasion, Fluorometric |
|||
| CBA-111 | Cell Biolabs | 12 assays | 714 EUR |
|
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 24-well plates on either a standard microplate reader or a fluorescence plate reader. Inserts are precoated on the top of the membrane with ECM matrix gel (basement membrane), a protein mix isolated from EHS tumor cells. |
|||
CytoSelect 96-well Cell Invasion, Fluorometric |
|||
| CBA-112 | Cell Biolabs | 96 assays | 908.4 EUR |
|
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect 96-Well Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 96-well plates on a fluorescence plate reader. Inserts are precoated on the top of the membrane with Basement Membrane, an ECM protein mix isolated from EHS tumor cells. |
|||
CytoSelect Cell Viability and Cytotoxicity Assay |
|||
| CBA-240 | Cell Biolabs | 96 assays | 470.4 EUR |
|
Description: The CytoSelect Cell Viability and Cytotoxicity Assay Kit provides a simple format for monitoring cell viability via metabolic activity. Live cells are detected with either MTT (colorimetric detection) or Calcein AM (fluorometric detection). Dead cells are detected by EthD-1 reagent (fluorometric). All 3 detection reagents are included, along with Saponin (a cell death initiator). Prior to the assay, cells may be treated with compounds or agents that affect cell viability. This kit is suitable for eukaryotic cells, not yeast or bacteria. |
|||
RRAD Blocking Peptide |
|||
| 20-abx063234 | Abbexa |
|
|
RRAD Blocking Peptide |
|||
| 33R-10070 | Fitzgerald | 100 ug | 216 EUR |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
|||
RRAD Blocking Peptide |
|||
| 33R-4793 | Fitzgerald | 100 ug | 216 EUR |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797 |
|||
CytoSelect 24-Well Cell Co-Culture System |
|||
| CBA-160 | Cell Biolabs | 24 assays | 525.6 EUR |
|
Description: CytoSelect 24-Well Cell Co-Culture System provides a unique platform to monitor direct contact between two cell types in a single well. First, cells are cultured until they form a monolayer around the insert, creating a defined 8 mm cell-free zone. Once the insert is removed, a second cell type may be seeded into the exposed zone. The kit contains proprietary treated inserts and sufficient reagents for the evaluation of 24 samples. The inserts are compatible with most adherent cell types and experimental conditions. |
|||
CytoSelect 24-Well Cell Co-Culture System |
|||
| CBA-160-5 | Cell Biolabs | 5 x 24 assays | 2078.4 EUR |
|
Description: CytoSelect 24-Well Cell Co-Culture System provides a unique platform to monitor direct contact between two cell types in a single well. First, cells are cultured until they form a monolayer around the insert, creating a defined 8 mm cell-free zone. Once the insert is removed, a second cell type may be seeded into the exposed zone. The kit contains proprietary treated inserts and sufficient reagents for the evaluation of 24 samples. The inserts are compatible with most adherent cell types and experimental conditions. |
|||
RRAD Protein Vector (Human) (pPM-C-HA) |
|||
| PV127328 | ABM | 500 ng | 662.4 EUR |
CytoSelect 48-Well Cell Contraction Assay Kit |
|||
| CBA-5021 | Cell Biolabs | 48 assays | 762 EUR |
|
Description: Cell Biolabs? Cell Contraction Assays (Floating Matrix Model) provide a simple, in vitro system to assess cell contractivity and screen cell contraction mediators. The proprietary Cell Contraction Plate eliminates the matrix releasing step of the conventional contraction assay, providing a faster, higher-throughput method to assess cell contraction. |
|||
CytoSelect Cell Proliferation Assay Reagent (Fluorometric) |
|||
| CBA-250 | Cell Biolabs | 10 mL | 490.8 EUR |
|
Description: Cell Biolabs? CytoSelect Cell Proliferation Assay Reagent (Fluorometric) provides a fluorometric format for measuring and monitoring cell proliferation. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then incubated with the proliferation reagent. Upon entering metabolically active live cells, the non-fluorescent proliferation reagent is converted into a bright red fluorescent form. An increase in cell proliferation is accompanied by increased fluorescent signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. The kit contains sufficient reagents for the evaluation of 960 assays in ten 96-well plates or 192 assays in eight 24-well plates. |
|||
CytoSelect Cell Proliferation Assay Reagent (Colorimetric) |
|||
| CBA-253 | Cell Biolabs | 10 mL | 490.8 EUR |
|
Description: Cell Biolabs? CytoSelect WST-1 Cell Proliferation Assay Reagent provides a colorimetric format for measuring and monitoring cell proliferation. The 10 mL volume is sufficient for the evaluation of 960 assays in ten 96-well plates or 192 assays in eight 24-well plates. Cells can be plated and then treated with compounds or agents that affect proliferation. Cells are then detected with the proliferation reagent, which is converted in live cells from WST-1 to the formazan form in the presence of cellular NADH and an electron mediator. An increase in cell proliferation is accompanied by increased signal, while a decrease in cell proliferation (and signal) can indicate the toxic effects of compounds or suboptimal culture conditions. The assay principles are basic and can be applied to most eukaryotic cell lines, including adherent and non-adherent cells and certain tissues. This cell proliferation reagent can be used to detect proliferation in bacteria, yeast, fungi, protozoa as well as cultured mammalian and piscine cells. |
|||
Rrad sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7052705 | ABM | 3 x 1.0 ug | 451.2 EUR |
AAVS1 Safe Harbor Targeting Vector 2.0 - GOI Knock-in Donor (AAVS1-SA-puro-EF1-MCS) |
|||
| GE622A-1 | SBI | 10 ug | 1128 EUR |
RRAD Protein Vector (Human) (pPB-C-His) |
|||
| PV127326 | ABM | 500 ng | 662.4 EUR |
However, once we additional carried out a sensitivity analysis, FPRP, and BFDP take a look at, less-credible optimistic outcomes had been recognized (all FPRP > 0.2 and BFDP > 0.8) in any important affiliation.In abstract, this research strongly signifies that every one important associations had been much less credible optimistic outcomes, fairly than from true associations.